RELIEF: The Changing Landscape of Axial Spondyloarthritis: Current and Emerging Agents for Individualized Treatment
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
R.J. Fasenmyer Chair of Clinical Immunology
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Daniel J. Wallace, MD, FACP, MACR
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
In affiliation with Attune Health
Los Angeles, California
This case-based enduring activity will cover the treatment and management of patients with axial spondyloarthritis.
This activity is intended for rheumatologists and other healthcare professionals involved in the management of patients with axial spondyloarthritis.
After completing the CME activity, learners should be better able to:
- Examine the specific domains of axial spondyloarthritis (AxSpA) and their relationship to quality of life
- Review current and emerging therapies used for AxSpA
- Evaluate the IL-17/23 axis and its relationship to the pathophysiology of AxSpA
- Compare outcomes measures used in clinical trials versus those that may be more practical for use in clinical practice
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this web-based activity for a maximum of 1.5 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with axial spondyloarthritis.
CNE Credits: 1.5 ANCC Contact Hours.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.5 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Leonard H. Calabrese, DO has received consulting fees from AbbVie, Genentech, Gilead, Horizon, Janssen, Lilly, Novartis, and Pfizer, and has served on speaker’s bureaus for AbbVie, Genentech, Horizon, Janssen, Lilly, and Novartis.
Daniel J. Wallace, MD, FACP, MACR has nothing to disclose.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group has nothing to disclose.
Chris Drury, Medical Director of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: February 18, 2020
EXPIRATION DATE: February 18, 2021